Affordable Access

deepdyve-link
Publisher Website

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.

Authors
  • Gozzetti, Alessandro1
  • Capochiani, Enrico2
  • Bocchia, Monica3
  • 1 Division of Hematology, University of Siena, Siena, Italy. [email protected] , (Italy)
  • 2 Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy. , (Italy)
  • 3 Division of Hematology, University of Siena, Siena, Italy. , (Italy)
Type
Published Article
Journal
Leukemia
Publisher
Springer Nature
Publication Date
Oct 01, 2020
Volume
34
Issue
10
Pages
2815–2816
Identifiers
DOI: 10.1038/s41375-020-01038-8
PMID: 32879427
Source
Medline
Language
English
License
Unknown
Report this publication

Statistics

Seen <100 times